These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8791009)

  • 41. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interaction of amino acid residues at positions 8-15 of secretin with the N-terminal domain of the secretin receptor.
    Gourlet P; Vilardaga JP; De Neef P; Vandermeers A; Waelbroeck M; Bollen A; Robberecht P
    Eur J Biochem; 1996 Jul; 239(2):349-55. PubMed ID: 8706739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cloning and expression of the human vasoactive intestinal peptide receptor.
    Sreedharan SP; Robichon A; Peterson KE; Goetzl EJ
    Proc Natl Acad Sci U S A; 1991 Jun; 88(11):4986-90. PubMed ID: 1675791
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship.
    Nicole P; Du K; Couvineau A; Laburthe M
    J Pharmacol Exp Ther; 1998 Feb; 284(2):744-50. PubMed ID: 9454823
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation.
    Hashimoto H; Ogawa N; Hagihara N; Yamamoto K; Imanishi K; Nogi H; Nishino A; Fujita T; Matsuda T; Nagata S; Baba A
    Mol Pharmacol; 1997 Jul; 52(1):128-35. PubMed ID: 9224822
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Construction of chimeras between human VIP1 and secretin receptors: identification of receptor domains involved in selectivity towards VIP, secretin, and PACAP.
    Du K; Nicole P; Couvineau A; Laburthe M
    Ann N Y Acad Sci; 1998 Dec; 865():386-9. PubMed ID: 9928035
    [No Abstract]   [Full Text] [Related]  

  • 47. Receptor-mediated actions of growth hormone releasing factor on granulosa cell differentiation.
    Moretti C; Bagnato A; Solan N; Frajese G; Catt KJ
    Endocrinology; 1990 Nov; 127(5):2117-26. PubMed ID: 2171907
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Functional and molecular properties of the human recombinant Y4 receptor: resistance to agonist-promoted desensitization.
    Voisin T; Goumain M; Lorinet AM; Maoret JJ; Laburthe M
    J Pharmacol Exp Ther; 2000 Feb; 292(2):638-46. PubMed ID: 10640301
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of introduction of an arginine16 in VIP, PACAP and secretin on ligand affinity for the receptors.
    Gourlet P; Vandermeers A; Vandermeers-Piret MC; De Neef P; Waelbroeck M; Robberecht P
    Biochim Biophys Acta; 1996 Dec; 1314(3):267-73. PubMed ID: 8982281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Presence of a N-terminal signal peptide in class II G protein-coupled receptors: crucial role for expression of the human VPAC1 receptor.
    Couvineau A; Rouyer-Fessard C; Laburthe M
    Regul Pept; 2004 Dec; 123(1-3):181-5. PubMed ID: 15518910
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of vasoactive intestinal peptide receptors on rat alveolar macrophages.
    Sakakibara H; Shima K; Said SI
    Am J Physiol; 1994 Sep; 267(3 Pt 1):L256-62. PubMed ID: 7943252
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT-29.
    Couvineau A; Rousset M; Laburthe M
    Biochem J; 1985 Oct; 231(1):139-43. PubMed ID: 2998337
    [TBL] [Abstract][Full Text] [Related]  

  • 53. VIP receptor subtypes in mouse cerebral cortex: evidence for a differential localization in astrocytes, microvessels and synaptosomal membranes.
    Martin JL; Feinstein DL; Yu N; Sorg O; Rossier C; Magistretti PJ
    Brain Res; 1992 Jul; 587(1):1-12. PubMed ID: 1326373
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacology and molecular identification of vasoactive intestinal peptide (VIP) receptors in normal and cancerous gastric mucosa in man.
    Gespach C; Bawab W; Chastre E; Emami S; Yanaihara N; Rosselin G
    Biochem Biophys Res Commun; 1988 Mar; 151(2):939-47. PubMed ID: 2831906
    [TBL] [Abstract][Full Text] [Related]  

  • 55. VIP and PACAP receptor pharmacology: a comparison of intracellular signaling pathways.
    Dickson L; Aramori I; Sharkey J; Finlayson K
    Ann N Y Acad Sci; 2006 Jul; 1070():239-42. PubMed ID: 16888173
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of mitogen-stimulated proliferation of murine splenocytes by a novel neuropeptide, pituitary adenylate cyclase activating polypeptide: a comparative study with vasoactive intestinal peptide.
    Tatsuno I; Gottschall PE; Arimura A
    Endocrinology; 1991 Feb; 128(2):728-34. PubMed ID: 1989859
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High affinity receptors for vasoactive intestinal peptide on a human glioma cell line.
    Nielsen FC; Gammeltoft S; Westermark B; Fahrenkrug J
    Peptides; 1990; 11(6):1225-31. PubMed ID: 1965033
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hypophysiotropic action of pituitary adenylate cyclase-activating polypeptide (PACAP) in the goldfish: immunohistochemical demonstration of PACAP in the pituitary, PACAP stimulation of growth hormone release from pituitary cells, and molecular cloning of pituitary type I PACAP receptor.
    Wong AO; Leung MY; Shea WL; Tse LY; Chang JP; Chow BK
    Endocrinology; 1998 Aug; 139(8):3465-79. PubMed ID: 9681497
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [D-Phe4]peptide histidine-isoleucinamide ([D-Phe4]PHI), a highly selective vasoactive-intestinal-peptide (VIP) agonist, discriminates VIP-preferring from secretin-preferring receptors in rat pancreatic membranes.
    Robberecht P; Coy DH; De Neef P; Camus JC; Cauvin A; Waelbroeck M; Christophe J
    Eur J Biochem; 1987 Jun; 165(2):243-9. PubMed ID: 3036504
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Demonstration of [125I]VIP binding sites and effects of VIP on cAMP-formation in rat insulinoma (RINm5F and RIN14B) cells.
    Andersson M; Sillard R; Rökaeus A
    Regul Pept; 1992 Jul; 40(1):41-9. PubMed ID: 1332138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.